Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Classical hematology 1

Conditions

Polycythemia Vera 11Brain Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Leukemia, Myeloid, Chronic-Phase 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Leukemia 9Glioblastoma 9Leukemia, Myeloid, Acute 8Meningioma 7Head and Neck Neoplasms 7Gliosarcoma 6Myelodysplastic Syndromes 4Glioma 4Central Nervous System Neoplasms 4Neoplasms 3Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Laryngeal Neoplasms 3Esophageal Neoplasms 3Treatment-Refractory Solid Tumors 2Thrombocythemia, Essential 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Primary Myelofibrosis 2Pharyngeal Neoplasms 2Paranasal Sinus Neoplasms 2Oropharyngeal Neoplasms 2Myelodysplastic-Myeloproliferative Diseases 2Hypopharyngeal Neoplasms 2

Interventions

Cyclophosphamide 78fludarabine phosphate 77Azacitidine 76Peripheral Blood Stem Cell Transplantation 63Busulfan 53Mycophenolic Acid 51Whole-Body Irradiation 50Tacrolimus 48Cytarabine 43Cyclosporine 43Methotrexate 37Decitabine 36Filgrastim 32Antilymphocyte Serum 30venetoclax 27Radiotherapy 25Melphalan 23fludarabine 22Etoposide 18Methylprednisolone 17Biopsy 15Cyclosporins 14Specimen Handling 13Injections 13Granulocyte Colony-Stimulating Factor 13Flow Cytometry 13Cord Blood Stem Cell Transplantation 13decitabine and cedazuridine drug combination 12Idarubicin 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × Hydroxyurea × Clear all
NCT07033598 2026-03-05

PROSPERA

Theradex

Phase 2 Recruiting
66 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT00005823 2013-12-18

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 3 Completed
2,000 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00083187 2013-07-18

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

National Cancer Institute (NCI)

Phase 2 Completed
230 enrolled
MyeloidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡